Additionally, PTGER4‐high tumours exhibited sensitivity to 12 targeted therapies, including MEK inhibitors (Trametinib) and BTK inhibitors (Ibrutinib), suggesting combinatorial therapeutic strategies. This evidence concerns the gene BTK and neoplasm.